The study, published in Cellular and Molecular Life Sciences, tested empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in a well-established animal model of aneurysm disease. Male ApoE-deficient mice, which are highly susceptible to vascular pathology, were infused with angiotensin II to trigger abdominal aortic aneurysm formation. One group of animals received the drug at a dose of 3 milligrams per kilogram per day for 28 days. The differences at the end of the study were striking. Among the aneurysm animals, 73.3 percent developed the disease; among those treated with empagliflozin, only 26.6 percent did. Maximum aortic diameter was significantly reduced, aortic rupture became far less common, and survival improved from 73.3 percent to 86.7 percent, a difference the authors report as statistically significant.

Abdominal aortic aneurysm is a permanent, irreversible dilation of the aorta that grows silently over years and can rupture without warning. Rupture carries mortality rates that exceed 80 percent in many settings, and because no drug is currently approved to slow or prevent the disease, the only definitive treatment is surgical repair, typically once the vessel exceeds a critical diameter. The search for a medical therapy has been one of the most persistent unmet needs in vascular medicine, which is why the idea that a glucose-lowering agent might double as an aneurysm-protective drug has generated considerable interest.

What makes the new findings remarkable is not only the magnitude of protection but the mechanism the investigators uncovered. Empagliflozin was already known to deliver cardiovascular benefits beyond its glucose-lowering effects, but this study is among the first to show that its protective activity in aneurysm disease depends on the gut microbiome. When the researchers depleted the animals’ gut bacteria with antibiotics, the drug lost virtually all of its aneurysm-fighting power. Conversely, when they transplanted fecal microbes from empagliflozin-treated mice into untreated animals, the recipients gained the drug’s benefits, showing reduced aneurysm incidence, diminished vascular inflammation, and stronger intestinal barriers. In effect, the microbiome was both necessary and sufficient to transfer the protection.

To understand how a diabetes drug reshapes microbial communities, the team performed 16S rRNA sequencing on fecal samples from each experimental group. The sequencing revealed a clear restructuring of the gut ecosystem. At the phylum level, empagliflozin increased the abundance of Tenericutes, a lesser-known bacterial lineage. At the genus level, the drug enriched several taxa, including Sutterella, Allobaculum, Colinsella, and Pelomonas, while reducing Methylobacterium. Functional prediction analysis using PICRUSt2 suggested shifts in microbial metabolic pathways, indicating that the drug’s influence extended beyond simple taxonomic changes to the biochemical work performed by the community as a whole.

Metabolic readouts confirmed those structural shifts. Targeted liquid chromatography coupled to tandem mass spectrometry showed empagliflozin-associated changes in fecal short-chain fatty acids, the beneficial microbial metabolites that nourish the gut lining and dampen systemic inflammation, as well as changes in plasma trimethylamine N-oxide, a metabolite produced by gut bacteria that has been repeatedly linked to cardiovascular disease. The drug simultaneously raised protective metabolites and lowered harmful ones, tilting the gut’s chemical output in a direction associated with vascular health.

The vascular consequences were equally measurable. In the aortic tissue of aneurysm animals, empagliflozin reduced the infiltration of inflammatory cells, preserved the integrity of elastic fibers in the vessel’s medial layer, and suppressed the angiotensin II-driven upregulation of matrix metalloproteinases, the tissue-destroying enzymes that digest the aortic wall. Levels of MMP9 and MMP2, both central players in aneurysm development, were significantly lower in treated animals. These enzymes are the molecular scissors that progressively weaken the artery; restraining them is widely considered the key pharmacological goal in aneurysm research.

The gut side of the story proved just as important. Aneurysm-inducing angiotensin II damages the intestinal barrier, allowing bacterial products such as lipopolysaccharide to leak into the bloodstream and inflame distant organs, including the aorta. Empagliflozin reversed this damage. Treated mice showed restored intestinal villus structure, upregulated expression of the tight-junction proteins ZO-1 and Occludin at both the mRNA and protein levels, reduced intestinal permeability, and markedly lower plasma lipopolysaccharide concentrations. Downstream in the aortic wall, the drug attenuated TLR4/NF-κB signaling, the classical inflammatory pathway activated by bacterial products that drives the chronic inflammation underlying aneurysm growth.

Assembled together, the evidence outlines a coherent biological circuit. Empagliflozin reshapes the gut microbiota, enriching beneficial taxa and shifting metabolite production toward short-chain fatty acids. Those changes restore the integrity of the intestinal barrier, preventing bacterial toxins from crossing into the circulation. With fewer circulating toxins, TLR4/NF-κB inflammation in the aortic wall subsides, destructive metalloproteinases are restrained, elastic fibers survive, and the artery remains structurally sound. The antibiotic depletion and fecal transplantation experiments serve as the causal linchpins of this model, demonstrating that the gut microbial community is the mediator through which the drug exerts its vascular protection rather than an incidental bystander.

The findings carry implications that extend well beyond aneurysm research. They suggest that some of the cardiovascular benefits of SGLT-2 inhibitors, a drug class already credited with unexpected heart and kidney protection in large clinical trials, may be mediated in part through the gut. They also point toward microbiome-based strategies for aneurysm prevention, whether through drugs, diet, or microbial therapies, in a disease where medicine currently offers nothing between surveillance and surgery. The authors are careful to frame the work as experimental: the results come from mice given angiotensin II, and human aneurysms develop over decades in a very different physiological context. Clinical trials in patients will be needed to determine whether empagliflozin, or the microbial signatures it promotes, can slow aneurysm growth in people. Still, the study provides a novel preventive strategy and a clear mechanistic target, the gut microbiota and intestinal barrier axis, for a disease that has lacked one. For the millions of patients carrying small, silently enlarging aneurysms, the possibility that a widely available drug might one day stop the growth is a prospect worth watching closely, and the gut, once again, sits at the center of the story.

Subject of Research: Gut microbiome-mediated protective effects of the SGLT-2 inhibitor empagliflozin against experimental abdominal aortic aneurysm formation and progression

Article Title: Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression

Article References: Guo, W., Hu, H., Wang, S., Li, D., Li, C., Chen, X., Deng, D., Xiao, J., Shen, Y., & Wei, Z. (2026). Gut microbiome mediates the protective effects of empagliflozin on experimental abdominal aortic aneurysm formation and progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06449-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06449-x

Keywords: abdominal aortic aneurysm, empagliflozin, SGLT-2 inhibitor, gut microbiota, intestinal barrier, inflammation, 16S rRNA sequencing, short-chain fatty acids, TMAO, TLR4/NF-κB signaling, MMP9, fecal microbiota transplantation